| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c213ba9952360f439567152e047b18 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 |
| filingDate |
2000-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2005-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3215d1fee1549c8c1942fb9c452cef20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d9bef3df4255e104ba30764428efd4b |
| publicationDate |
2005-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6924359-B1 |
| titleOfInvention |
Neovascular-targeted immunoconjugates |
| abstract |
Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019067249-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006052286-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017083791-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004009914-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006229239-A9
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018207292-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008206227-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020085922-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010015160-A1 |
| priorityDate |
1999-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |